You need to be logged in to view this video
John McCamant, editor of the Medical Technology Stock Letter, says he expects a bidding war for MYOV and important catalysts from MDGL, TCRT, and PGEN in Q4.
John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.
Filter By Category
Filter By Keywords